VAR2 will be represented by its COO, Andreas Linderoth Norlin, at this year’s BIO International Convention taking place in Boston 4th to 7th June. We look forward to a great program and many exciting meetings with old and new partners in the biopharma business. See you there!
VAR2 Pharmaceuticals co-authors have published an article in Nature Communications entitled “Cryo-EM reveals the architecture of placental malaria VAR2CSA and provides molecular insight into chondroitin sulfate binding”. This article reports the high-resolution structure of our proprietary cancer targeting molecule, VAR2CSA, and sheds light on the complex interaction between VAR2CSA and oncofetal chondroitin sulfate in tumors […]
On May 3rd 2019 Co-founder and Chairman of the Board, Dr. Mads Daugaard, was awarded St. Baldrick’s Foundation Awards One-of-a-Kind Grant to Aid in Childhood Cancer Research Discovery for his work to identify and exploit secondary modifications of proteins as targets for novel experimental immunotherapies. We are very proud and happy for this appreciation of Dr. Daugaard’s great personal acheivements. […]
Our website only uses strictly necessary cookies. Please consult our Privacy Policy for additional information on how we process your data.